- Company enters next stage of expansion after a period of successful strategic and operational progress
- Uwe Buecheler, PhD, Vice Chairman of the Supervisory Board, named interim CEO
LAUPHEIM, Germany and MILFORD, Mass., Jan. 20, 2026 — Rentschler Biopharma SE, a premier contract development and manufacturing organization (CDMO) for biopharmaceuticals, today declared adjustments to its Executive Board. These modifications coincide with the company’s execution of the subsequent stage of its corporate strategy, designed to further reinforce long-term expansion and sustainable value generation.
The Supervisory Board and Benedikt von Braunmuehl, Chief Executive Officer (CEO), have mutually concluded that Mr. von Braunmuehl will resign from the Executive Board, and the corporate strategy will be carried out under fresh leadership. To guarantee continuity and complete operational efficiency, Uwe Buecheler, PhD, Vice Chairman of the Supervisory Board, will take on the position of interim Chief Executive Officer, effective immediately, until a permanent CEO is named.
“Mr. von Braunmuehl rapidly established crucial groundwork and played a key role in defining the market position Rentschler Biopharma holds today. With this phase now successfully concluded, the moment has arrived to hand over the strategy’s execution to a new leadership team. The Supervisory Board extends its sincere gratitude to Mr. von Braunmuehl for his substantial and highly successful contributions to the company’s evolution and wishes him ongoing success and the best in his future pursuits,” stated Nikolaus F. Rentschler, PhD, Chairman of the Supervisory Board of Rentschler Biopharma.
“I extend my thanks to all my colleagues for their commitment and the robust cooperation across all departments and locations. Rentschler Biopharma is in an excellent position for a prosperous future, and I wish the whole team continued achievement on this path,” stated Benedikt von Braunmuehl, Chief Executive Officer.
In a separate announcement, the company confirmed that Christiane Bardroff, Chief Operating Officer (COO), has chosen to explore a new career path after four years with Rentschler Biopharma and will depart in the first quarter of this year. Her replacement has already been selected by the Supervisory Board and will be introduced at the appropriate time.
Nikolaus F. Rentschler, PhD, remarked: “Throughout her time as COO, Ms. Bardroff spearheaded major operational enhancements and successfully progressed critical initiatives. These encompass the installation of a new production line at the Milford, MA facility, the considerable boost in production output in Laupheim via efficiency programs, and the design of the new buffer media station. Through her emphasis on operational excellence, quality, digitalization, and automation, she delivered significant momentum for our company’s ongoing progress. The Supervisory Board sincerely appreciates Ms. Bardroff for her devotion, hard work, and collaborative partnership and wishes her great success and all the best in her future endeavors.”
“I am delighted that Uwe Buecheler will take up the post of interim Chief Executive Officer. He was deeply engaged in crafting our strategy and possesses extensive international leadership experience in steering through market changes and strategic choices. He is fully prepared to lead Rentschler Biopharma through this period, with the aim of generating sustainable value – for our clients, their patients, and the markets we serve,” said Nikolaus F. Rentschler, PhD.
Uwe Buecheler, PhD, interim CEO, stated: “Rentschler Biopharma is presently in a robust operational and financial state. Leveraging the expansion of our production capacity, our exceptional development capabilities, and successful efficiency gains across our locations, we are steering Rentschler Biopharma into its next development chapter, which will place even greater emphasis on client satisfaction, closeness to clients, and business growth. My priority is to collaborate closely with our CFO Gunnar Voss von Dahlen, the soon-to-join COO, and our highly driven teams in Laupheim and Milford to efficiently execute the corporate strategy. For our global clients, we will remain a dependable partner in bioprocess development and biopharmaceutical manufacturing, driven by our mission of progressing medicine to save lives. Together.”
Uwe Buecheler, PhD, contributes more than thirty years of expertise in the worldwide biopharmaceutical industry and the contract development and manufacturing field. He has held the role of Vice Chairman of the Supervisory Board of Rentschler Biopharma since 2024. His knowledge covers leadership, operations, and technology development. He has also been instrumental in many global regulatory approvals and expansion initiatives, adding to his global outlook and strategic insight.
About Rentschler Biopharma SE
Rentschler Biopharma is a top-tier contract development and manufacturing organization (CDMO) dedicated solely to client initiatives. The firm provides process development and manufacturing of biopharmaceuticals, along with associated consulting services, project management, and regulatory assistance. Rentschler Biopharma’s superior quality is demonstrated by its extensive history and proficiency as a solutions provider for its clients. A sophisticated quality management system, a deeply ingrained operational excellence culture, and cutting-edge technologies guarantee product quality and productivity at every stage of development and manufacturing. Rentschler Biopharma is a family-run enterprise with approximately 1,400 staff, based in Laupheim, Germany, with a site in Milford, MA, USA. In 2024, the company became a participant in the United Nations Global Compact, highlighting Rentschler Biopharma’s dedication to sustainability.
For more information, please visit: . Follow Rentschler Biopharma on .
Contact:
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Global Head of Communications
Phone: +49-7392-701-467
Media inquiries
| MC Services AG Eva Bauer Phone: +49-89-210228-0 |
U.S. Laurie Doyle Phone: +1-339-832-0752 |
